Methods and compositions for the preparation of cell transplants

Abstract

The present invention relates to a method for the cultivation of eucaryotic cells, the use of cells cultured according to said method for the preparation of in particular autologous, but also allogenous (cell) transplants, as well as JIM particular the use of accordingly prepared autologous melanocyte and/or keratinocyte transplants for the treatment of vitiligo patients; furthermore, also to melanocyte and/or keratinocyte transplants prepared accordingly. The present invention furthermore relates to new compositions comprising melanocytes as Well as their use for the treatment of vitiligo patients; furthermore to the use of compositions comprising keratiziocytes for the treatment of various dermatological symptoms and diseases.

1 . Method for the cultivation of eucaryotic cells, characterized in that steps in which the cell cultures are open are carried out under conditions complying with the requirements of sterility class “A” according to the GMP-Guidelines.  
     
     
         2 . Method according to    claim 1   , characterized in that steps in which the cell cultures are open are carried out in a closed system at overpressure.  
     
     
         3 . Method according to    claim 1   , characterized in that human cells are cultured.  
     
     
         4 . Method according to    claim 2   , characterized in that skin cells bone cells, cartilage cells, adipocytes, vessel cells, cells of the oral mucous membrane, urothelial cells, muscle cells, cells of the nervous -system, haematopoetic cells, tendon cells, other cells of the motility system, embryonic and other stem cells, liver calls, kidney cells, heart muscle cells, epithelial cells or various mucous membranes as well as hormone- or transmitter- producing cells are cultured.  
     
     
         5 . Use of eucaryotic cells cultured according to    claim 1    as an autologous transplant or for the preparation of an autologous transplant or a three-dimensional tissue substitution material.  
     
     
         6 . Use of eucaryotic cells cultured according to    claim 2    as an autologous transplant or for the preparation of an autologous transplant or a three-dimensional tissue substitution material.  
     
     
         7 . Use of eucaryotic cells cultured according to    claim 3    as an autologous transplant or for the preparation of an autologous transplant or a three-dimensional tissue substitution material.  
     
     
         8 . Use of eucaryotic cells cultured according to    claim 4    as an autologous transplant or for the preparation of an autologous transplant or a three-dimensional tissue substitution material.  
     
     
         9 . Use according to    claim 5    characterized in that said autologous transplants comprise skin cells, cells of the oral mucous membrane, cartilage cells, bone cells and/or adipocytes in a matrix based upon biological molecules, in particular on extracellular matrix molecules or derivatives thereof or on synthetic molecules.  
     
     
         10 . Use according to    claim 6    characterized in that said autologous transplants comprise skin cells, cells of the oral mucous membrane, cartilage cells, bone cells and/or adipocytes in a matrix based upon biological molecules, in particular on extracellular matrix molecules or derivatives thereof or on synthetic molecules.  
     
     
         11 . Use according to    claim 7    characterized in that said autologous transplants comprise skin cells, cells of the oral mucous membrane, cartilage cells, bone cells and/or adipocytes in a matrix based upon biological molecules, in particular on extracellular matrix molecules or derivatives thereof or on synthetic molecules.  
     
     
         12 . Use according to    claim 8    characterized in that said autologous transplants comprise skin cells, cells of the oral mucous membrane, cartilage cells, bone cells and/or adipocytes in a matrix based upon biological molecules, in particular on extracellular matrix molecules or derivatives thereof or on synthetic molecules.  
     
     
         13 . Use of hormone- or transmitter-producing cells cultured according to    claim 4    in combination with suitable capsules as allogenous transplants or for the preparation of allogenous transplants.  
     
     
         14 . Transplant comprising melanocytes and/or keratinocytes characterized in that said melanocytes; and/or keratinocytes are cultured according to    claim 1   .  
     
     
         15 . Composition suitable for transplantation comprising melanocytes in a carrier matrix.  
     
     
         16 . Composition according to    claim 15   , characterized in that said carrier matrix exhibits plasticity or gel-like consistency.  
     
     
         17 . Composition according to    claim 16   , characterized in that said carrier matrix is based upon biomolecules and/or synthetic materials.  
     
     
         18 . Composition according to    claim 17   , characterized in that carrier matrix is based upon fibrin glue.  
     
     
         19 . Use of a composition according to    claim 15    as autologous transplant or for the preparation of an autologous transplant for the treatment of vitiligo patients.  
     
     
         20 . Use according to    claim 19    characterized in that said treatment of vitiligo patients comprises the following steps: 
 i. pretreatment by ER-YAG-laser;  
 ii. transplantation of a composition according to any one of the    claims 9    to    12    or comprising melanocytes cultured according to any one of the claims I to  4 ; as well as  
 iii. posttreatment by UV-radiation.  
 
     
     
         21 . Use of a composition suitable for transplantation comprising keratinocytes cultured according to    claim 1    as an antologous transplant or for the preparation of an autologous transplant for the treatment of vitiligo patients.  
     
     
         22 . Use of compositions comprising keratinocytes as autologous transplant or for the preparation of an autologous transplant for the treatment (a) of solar pre-cancerous forms, (b) of pregnancy-induced changes in skin (e.g., chloasma), (c) of rosacea and rhinophyn (“lumpy nose”), (d) of age-induced changes in skin (e.g., formation of wrinkles), or (e) of keloids, hypertrophic scares, acne scares as well as of therapy-resistant acne.